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Background: Long noncoding RNAs (lncRNAs) have been identified as having functional roles in cancer biology
and are deregulated in many cancers. The present study aimed to determine the expression, roles and functional
mechanisms of a long noncoding RNA CCAT1 in the progression of hepatocellular carcinoma (HCC).
Methods: CCAT1 expression levels in 66 pairs of HCC tissues and pair-matched noncancerous hepatic tissues were
tested by real-time PCR. The effects of CCAT1 on HCC cells proliferation and migration were assessed using in vitro
cell proliferation and migration assays. A computational screen of microRNAs (miRNAs) target sites in CCAT1 was
conducted to search for specific miRNAs binding to CCAT1. The specific binding between CCAT1 and miRNAs was
confirmed by RNA immunoprecipitation assay combined with luciferase reporter assay.
Results: CCAT1 levels are markedly increased in HCC tissues compared with pair-matched noncancerous hepatic
tissues. Up-regulation of CCAT1 is correlated with tumor size, microvascular invasion, AFP and poor prognosis.
CCAT1 promotes the proliferation and migration of HCC cells. CCAT1 functions as a molecular sponge for let-7,
antagonizes its functions, and leads to the de-repression of its endogenous targets HMGA2 and c-Myc. The effect of
CCAT1 on HCC cell proliferation and migration is dependent upon its competitively binding to let-7.
Conclusions: These data suggest that CCAT1 plays a pivotal role in HCC progression via functioning as let-7
sponge, and implicate the potential application of CCAT1 for the prognosis and treatment of HCC.
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Hepatocellular carcinoma (HCC) is the fifth most common
solid tumor and the third leading cause of cancer-related
deaths worldwide [1]. Most cases of HCC are attributed
to chronic infection with either hepatitis B or C virus [2].
Unfortunately, unlike most malignancies, HCC patients
remain have poor prognosis and high recurrence rate
despite recent advances in surgical resection and medical
treatment [3-5]. It is of paramount importance to under-
stand the pathophysiological mechanisms contributing to
HCC for developing new diagnosis and treatment strat-
egies and improving the overall prognosis of HCC pa-
tients [6-8].* Correspondence: jihongzhangsyu@163.com
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unless otherwise stated.Long noncoding RNAs (lncRNAs), which are more
than 200 nucleotides in length with limited protein coding
potential, were recently identified as having functional
roles in a variety of biological processes and disease states
[9-13]. Notably, several lncRNAs are deregulated in many
cancers, and the deregulation has been shown to result in
aberrant gene expression that contributes to the progres-
sion of cancers, including HCC [14-17]. The overall
pathophysiological contributions of lncRNAs to HCC re-
main largely unknown. Recently a novel long noncoding
RNA colon cancer associated transcript-1 (CCAT1) was
shown to be consistently upregulated in gastric carcinoma
and colon cancer [18,19]. However, its expression, roles,
and function mechanisms in HCC are still unknown and
need to be investigated.
Recently, many RNA transcripts have been demon-
strated to function as competing endogenous RNAshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(miRNAs) [20-22]. These ceRNAs generally share miRNA
response elements with other transcripts targeted by
that set of miRNAs. So these ceRNAs can function as
sponges for that set of miRNAs, functionally preventing
these targeted transcripts from being degraded [23,24].
Therefore we propose that whether CCAT1 also has
roles as miRNAs sponges to modulate the functions of
miRNAs.
In this study we found that CCAT1 is upregulated in
human HCC tissues and is associated with poor progno-
sis. The upregulation of CCAT1 promotes the prolifera-




The 66 HCC tissues and their pair-matched noncan-
cerous hepatic tissues utilized in this study were ob-
tained with informed consent from patients who
underwent radical resections at the Eastern Hospital of
the First Affiliated Hospital, Sun Yat-sen University,
Guangzhou, China. This study was performed with the
approval of the Sun Yat-sen University Institutional Re-
view Board.
Cell culture
The human liver normal cell lines LO2 and QSG-7701,
human HCC cell lines SMMC-7721, Hep3B, Huh7, and
HepG2 were obtained from the Chinese Academy of Sci-
ences Cell Bank. The cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum (Gibco BRL, Gaithersburg, MD, USA), and
were maintained in a humidified 37°C incubator with an
atmosphere containing 5% CO2.
RNA extraction and real-time PCR
Total RNAs was isolated using Trizol reagent (Takara,
Dalian, China). First-strand cDNA was generated using
the Reverse Transcription System Kit (Invitrogen, Carlsbad,
CA, USA). Real-time PCR was performed using the stand-
ard SYBR Green PCR kit protocol in the StepOne Plus
system (Applied Biosystems, Foster City, CA, USA). 18S
rRNA was employed as an endogenous control for mRNA
and lncRNA. The primer sequences used were as follows:
for CCAT1, 5′-TTTATGCTTGAGCCTTGA-3′ (forward)
and 5′-CTTGCCTGAAATACTTGC-3′ (reverse); for 18S
rRNA, 5′-ACACGGACAGGATTGACAGA-3′ (forward)
and 5′-GGACATCTAAGGGCATCACA-3′ (reverse); for
HMGA2, 5′-TTCAGCCCAGGGACAACC-3′ (forward)
and 5′-CTTTTGAGCTGCTTTAGAGGG-3′ (reverse);
for c-Myc, 5′-GGGCTTTATCTAACTCGCTGTA-3′ (for-
ward) and 5′-GCTATGGGCAAAGTTTCGTG-3′ (re-
verse). For miRNA analysis, real-time PCR was performedas above, using TaqMan miRNA assays according to the
manufacturer’s instructions (Applied Biosystems). The real-
time PCR reactions were performed in triplicate. The
relative expression of RNAs was calculated using the
comparative Ct method.
Vectors construction
The complementary DNA encoding CCAT1 was PCR-
amplified by the Pfu Ultra II Fusion HS DNA Polymer-
ase (Stratagene, Agilent Technologies, Palo Alto, CA,
USA) and subcloned into the pcDNA3.1 vector (Invitro-
gen). The primers used were 5′-CTAGCTAGCACAAC
ATCGACTTTGAAGTT-3′ (forward) and 5′-CCCAAG
CTTAAGACTTAATATACTTATATTTA-3′ (reverse). The
pcDNA3.1-CCAT1 with point mutations in let-7 binding
sites was synthesized by GenScript (Nanjing, China) and
named pcDNA3.1-CCAT1-Mut. pSL-MS2-12X (Addgene)
was double digested with BamH I and Xba I, and the
MS2-12X fragment was subcloned into pcDNA3.1,
pcDNA3.1-CCAT1 or pcDNA3.1-CCAT1-Mut, named
pcDNA3.1-MS2, pcDNA3.1-MS2-CCAT1 or pcDNA3.1-
MS2-CCAT1-Mut respectively. The let-7 binding region
of either lncRNA-CCAT1 or lncRNA-CCAT1-Mut was
amplified using PCR and subcloned into the pmirGLO
vector (Promega, Madison, WI, USA) for Luciferase re-
porter assay. The primers used were 5′-CGAGCTCTC
AACCCTGACGCTCTTTCTG-3′ (forward) and 5′-GCT
CTAGATCACTCACCCACTGCTCACC-3′ (reverse).
Transient transfection
Transfections were performed using the Lipofectamine
3000 kit (Invitrogen) according to the manufacturer’s in-
structions. let-7 miRNA mimics hsa-let-7a, hsa-let-7b,
hsa-let-7c, and hsa-let-7e, miR negative control, anti-
miR has-let-7b miRNA inhibitor and anti-miR control
were purchased from Life Technologies (Ambion, Grand
Island, NY, USA) and introduced into cells at a final
concentration of 50 nM. The transfected cells were har-
vested at 48 hours after transfection.
Construction of stable cell lines with overexpression or
downregulation of CCAT1
To obtain cell lines stably expressing CCAT1, CCAT1-
Mut, SMMC-7721 cells were transfected with the plas-
mid pcDNA3.1-CCAT1 or pcDNA3.1-CCAT1-Mut, and
selected with neomycin (800 μg/ml) for four weeks. To
obtain cell lines stably suppressing CCAT1, SMMC-7721
cells were transfected with the plasmid pGPU6/GFP/
Neo-human-CCAT1 (designated shRNA-CCAT1) (Gen-
ePharma, Shanghai, China), and selected with neomycin
(800 μg/ml) for four weeks. The shRNA-CCAT1 se-
quences used were as follows: 5′-CACCCCATTCCATT
CATTTCTCTTTCCTATTCAAGAGATAGGAAAGAGA
AATGAATGGAATGGTTTTTTG-3′ (forward) and 5′-




A total of approximately 5 × 103 HCC cells were plated
in 96-well plates. After 24 h of culture, cell proliferation
was assessed using the Cell Counting Kit-8 (Dojindo,
Tokyo, Japan) according to the manufacturer’s protocol.
All experiments were performed in triplicate. The cell
proliferation curves were plotted using the absorbance
at each time point.
Colony formation assay
One or two hundred cells were plated into 6-well plates
and incubated in DMEM with 10% FBS at 37°C. Seven
days later, the cells were fixed and stained with 0.1%
crystal violet. The number of colonies, defined as >50
cells/colony, were counted.
Transwell assay
Transwell assays were performed using poly-carbonate
transwell filters (Corning, 8 μm) placed over the bottom
chambers that were filled with culture medium contain-
ing 20% FBS. A sample of 4 × 104 cells was suspended in
DMEM medium containing 1% FBS and seeded into the
upper well. After 48 h, cells on the upper surface of the
well were removed, and cells on the lower surface were
fixed in paraformaldehyde and stained with 0.4% crystal
violet. For each experiment, the number of transmi-
grated cells in five random fields on the underside of the
filter was counted and photographed, and three inde-
pendent filters were analyzed.
RNA immunoprecipitation (RIP)
SMMC-7721 cells were co-transfected with pcDNA3.1-
MS2, pcDNA3.1-MS2-CCAT1 or pcDNA3.1-MS2-CCAT1-
Mut and pMS2-GFP (Addgene). After 48 hrs, cells were
used to perform RIP experiments using a GFP antibody
(Roche, Mannheim, Germany) and the Magna RIP™
RNA-Binding Protein Immunoprecipitation Kit (Millipore,
Bedford, MA, USA) according to the manufacturer’s
instructions.
Luciferase reporter assay
pmirGLO, pmirGLO-CCAT1 or pmirGLO-CCAT1-Mut
was co-transfected with let-7 mimics or miR NC into
SMMC-7721 cells. The relative luciferase activity was
normalized to Renilla luciferase activity 48 hr after
transfection.
Western blot analysis
Total cell lysates were prepared in a 1× sodium dodecyl sul-
fate buffer. Identical quantities of proteins were separatedby sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis and transferred onto nitrocellulose membranes. After
incubation with antibodies specific for HMGA2, c-Myc
(Cell Signaling Technology) or β-actin (Sigma-Aldrich,
Saint Louis, MO, USA), the blots were incubated with
IRdye 800-conjugated goat anti-rabbit IgG or IRdye 700-
conjugated goat anti-mouse IgG and were detected using
an Odyssey infrared scanner (Li-Cor, Lincoln, NE, USA).
Immunohistochemical assay
Immunohistochemistry for the target molecules was per-
formed on paraffin sections using a primary antibody
against HMGA2 (Cell Signaling Technology, Boston,
USA), and a horseradish peroxidase-conjugated IgG (1:500;
Invitrogen), and the proteins in situ were visualized with
3, 3-diaminobenzidine. All slices were evaluated by two
pathologists without knowledge of the clinical outcome.
The staining intensities were evaluated in each sample and
graded on a scale of 0 to 9.
Statistical analysis
For comparisons, Student’s t-test, Wilcoxon signed-rank
test, Pearson chi-square test, Log-rank test, Pearson cor-
relation analysis, and Mann–Whitney U test were per-
formed as indicated. All p values were two-sided and
obtained using the SPSS 18.0 software package (SPSS,
Chicago, IL, USA). Differences were defined as statisti-
cally significant for p-values < 0.05.
Results
CCAT1 is upregulated in human HCC tissues and is
associated with poor prognosis
To explore the role of CCAT1 in HCC progression, we
first examined the expression of CCAT1 in four human
HCC cell lines (SMMC-7721, Hep3B, Huh7, and HepG2)
and two liver normal cell lines (LO2 and QSG-7701). As
shown in Figure 1A, elevated expression of CCAT1 was
observed in all four HCC cell lines compared with that in
liver normal cell lines. We then measured CCAT1 expres-
sion level in 66 pairs of HCC tissues and pair-matched
noncancerous hepatic tissues. As presented in Figure 1B,
the CCAT1 levels were significantly increased in HCC tis-
sues as compared with pair-matched noncancerous hep-
atic tissues (p < 0.001 by Wilcoxon signed-rank test).
We next analyzed the correlation between CCAT1 ex-
pression levels and the clinicopathologic characteristics
of the 66 HCC patients (Table 1). Correlation regression
analysis showed that high expression of CCAT1 was sig-
nificantly correlated with tumor size (p = 0.013), micro-
vascular invasion (p = 0.032), and AFP (p = 0.011).
We further examined whether the CCAT1 expres-
sion level was correlated with the outcome of HCC
patients. Kaplan-Meier survival estimates showed that
high CCAT1 expression in HCC tissues is significantly
Figure 1 CCAT1 expression in HCC and its association with patients’ prognosis. (A) Expression of CCAT1 in four HCC cell lines and two liver
normal cell lines. Data are presented as mean ± standard error based on at least three independent experiments. **p < 0.01, ***p < 0.001.
(B) Differences in CCAT1 expression levels between HCC tissues and pair-matched noncancerous hepatic tissues. The expression of CCAT1 was
normalized to that of 18S rRNA, which is an abundant and constitutively expressed non-coding RNA. Statistical differences between samples were
analyzed using the Wilcoxon signed-rank test (n = 66, p < 0.001). (C, D) Kaplan–Meier analyses of correlations between the CCAT1 expression level
and recurrence-free survival (C) or overall survival (D) of 66 HCC patients. The median expression level was used as the cut-off.
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log-rank test) and overall survival (p = 0.018, log-rank test)
(Figure 1C, D). These results indicate that CCAT1 may
play a pivotal role in the progression and malignant out-
comes of HCC.Enforced expression of CCAT1 promotes the proliferation
and migration of HCC cells
To investigate the biological functions of CCAT1 on
HCC, we stably enhanced CCAT1 expression by trans-
fecting CCAT1 expression vector (pcDNA3.1-CCAT1)
into the HCC cell lines SMMC-7721 and HepG2,
employing the pcDNA3.1 vector as a negative control
(Figure 2A). Cell-counting kit 8 (CCK-8) assays indicated
that enhanced expression of CCAT1 significantly pro-
moted cell proliferation in SMMC-7721 and HepG2 cells
(Figure 2B). Colony formation assays revealed that the
CCAT1 transfected SMMC-7721 and HepG2 cells
formed significantly more colonies than control SMMC-
7721 and HepG2 cells (Figure 2C). These results suggest
that CCAT1 plays an important role in regulating HCC
cell proliferation. To evaluate the migration efficiency of
HCC cells, transwell assays were performed. As pre-
sented in Figure 2D, enhanced expression of CCAT1significantly increased cell migration in SMMC-7721
and HepG2 cells.Attenuated expression of CCAT1 inhibits the proliferation
and migration of HCC cells
To further confirm the role of CCAT1 in HCC progres-
sion, we stably inhibited CCAT1 expression by trans-
fecting CCAT1-specific shRNA into SMMC-7721 and
HepG2 cells, using control shRNA as a negative control
(Figure 3A). As demonstrated by CCK-8 assays, repres-
sion of CCAT1 significantly decreased cell proliferation
in SMMC-7721 and HepG2 cells (Figure 3B). Colony for-
mation assays revealed that CCAT1 repressed SMMC-
7721 and HepG2 cells formed significantly less colonies
than control SMMC-7721 and HepG2 cells (Figure 3C).
As demonstrated by transwell assays, repression of
CCAT1 decreased cell migration (Figure 3D). These
data proved that CCAT1 play important roles in HCC
progression.CCAT1 acts as a molecular sponge for let-7
Recently, many lncRNAs have been reported to function
as sponges to bind specific miRNAs. To examine whether
CCAT1 has a similar mechanism, prediction of miRNA











HBs antigen 0.183 0.669
Positive 29 31
Negative 4 2
AFP (ug/L) 6.418 0.011
>20 20 29
≤20 13 4
Tumor size (cm) 6.111 0.013
>5 10 20
≤5 23 13






HBs antigen: hepatitis B surface antigen; AFP: alpha-fetoprotein.
#The median expression level was used as the cutoff. Low CCAT1 expression in
each of the 66 patients was defined as a value below the 50th percentile. High
CCAT1 expression in each of the 66 patients was defined as a value above the
50th percentile.
*For analysis of correlation between the expression levels of CCAT1 and clinical
features, Pearson chi-square tests were used. Results were considered statistically
significant at p < 0 .05.
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Inspector (http://bioinfo.uni-plovdiv.bg/microinspector/)
[25]. As shown in Figure 4A and Additional file 1: Table S1,
CCAT1 contains two predicted let-7 targeting sites. It has
been reported that let-7 inhibited tumor proliferation and
migration, and induced apoptosis [26,27]. So we focused
on let-7 as the primary candidate. To determine the direct
binding between let-7 and CCAT1 at endogenous levels,
we performed an RNA immunoprecipitation (RIP) to pull
down endogenous miRNAs associated with CCAT1 and
demonstrated via quantitative real-time PCR analysis
that the CCAT1 RIP in SMMC-7721 cells was signifi-
cantly enriched for let-7a, let-7b, let-7c, and let-7e com-
pared to IgG, the empty vector (MS2), and CCAT1 with
mutations in let-7 targeting sites (Figure 4B, C). In
CCAT1-expressing cells, the levels of the four let-7 sub-
types predicted to bind CCAT1 were not significantlychanged (Figure 4D). These data demonstrated that
CCAT1 bound let-7, but did not induce the degradation
of let-7. For further confirmation, we constructed lucif-
erase reporters containing CCAT1, which contains wild-
type (WT) or mutated let-7 binding sites, for target
investigates. We found that the let-7a, let-7b, let-7c, and
let-7e mimics reduced the luciferase activities of the WT
reporter vector but did not reduce the activity of the
empty vector and mutant reporter vector (Figure 4E),
supporting that let-7 are bona fide CCAT1-targeting
miRNAs. Next, we speculated as to whether the let-7
could alter the expression of CCAT1. After transfection
of let-7 mimics or the miRNA negative control into the
SMMC-7721, we measured the expression of CCAT1.
We found no significant difference in CCAT1 levels
after transfection (Figure 4F). These data demonstrated
that let-7 bound to CCAT1 but did not induce the deg-
radation of CCAT1. All these data suggest that CCAT1
physically associated with let-7 and may function as a
competing endogenous RNA for let-7.
CCAT1 modulated expression of endogenous let-7 targets
HMGA2 and c-Myc
To determine whether CCAT1 affects the expression of
endogenous let-7 targets, we stably overexpressed CCAT1
WT or CCAT1-Mut in SMMC-7721 cells. The overex-
pression level of mutant clone is similar to that of WT
overexpression clone (Figure 5A). The expression of two
known let-7 targets, HMGA2 and c-Myc, were analyzed in
CCAT1 stably overexpressed SMMC-7721 cells [28,29].
Overexpression of CCAT1 WT, but not the mutant, in-
creased c-Myc mRNA level (Figure 5B). Although the
mRNA level of HMGA2 was not changed, the protein
levels of HMGA2 and c-Myc were both upregulated by
overexpression of CCAT1 WT, but not the mutant
(Figure 5C). We also inhibited let-7 in CCAT1 down-
regulated HepG2 cells (Figure 5D, E). The inhibition of
CCAT1, on the other hand, decreased c-Myc mRNA level,
which is abolished by depletion of let-7 (Figure 5F). The
protein levels of HMGA2 and c-Myc were decreased by
inhibition of CCAT1, which is also abolished by depletion
of let-7 (Figure 5G). These data demonstrated that the
regulation of HMGA2 and c-Myc by CCAT1 was
dependent on the specific binding of let-7. Our results
were also consistent with the report that let-7 repressed
the translation of HMGA2 mRNA, but did not induce
HMGA2 mRNA degradation [30]. We next examined
whether CCAT1 is co-expressed with c-Myc and HMGA2
in human HCC samples. We measured the expression
levels of CCAT1 and c-Myc mRNA in the same set of 66
HCC tissues shown in Figure 1B. As shown in Figures 5H,
CCAT1 transcript level was significantly correlated with
c-Myc mRNA level. We also evaluated the immunohisto-
chemical score of HMGA2 protein expression in the
Figure 2 Enforced expression of CCAT1 promotes the proliferation and migration of HCC cells. (A) The expression of CCAT1 in SMMC-
7721 and HepG2 cells with CCAT1 stably overexpressed. (B) CCAT1 promotes the proliferation of SMMC-7721 and HepG2 cells. Cell number was
determined by the CCK-8 assay, and the relative number of cells to 0 h is presented. (C) The colony number of CCAT1 overexpressed SMMC-7721
and HepG2 cells per well in 6-well plates. (D) CCAT1 promotes cell migration by transwell assays. All values are presented as mean ± standard
error based on at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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of HMGA2 was significantly higher in CCAT1 high
expression group compared to that of CCAT1 low ex-
pression group (Figure 5I). All these data suggest an im-
portant role of CCAT1 in modulating HMGA2 and c-
Myc by competitively binding let-7.Figure 3 Attenuated expression of CCAT1 inhibits the proliferation an
7721 and HepG2 cells with CCAT1 stably repressed. (B) Repression of CCAT
number was determined by the CCK-8 assay, and the relative number of ce
SMMC-7721 and HepG2 cells per well in 6-well plates. (D) Repression of CC
presented as mean ± standard error based on at least three independent eCCAT1 promotes HCC progression by competitively
binding let-7
Functional assays were used to clarify the importance of
let-7 binding in promoting HCC progression by CCAT1.
CCK-8 assays indicated that the mutation of let-7 bind-
ing sites attenuated the promoting proliferation effect ofd migration of HCC cells. (A) The expression of CCAT1 in SMMC-
1 decreases the proliferation of SMMC-7721 and HepG2 cells. Cell
lls to 0 h is presented. (C) The colony number of CCAT1 repressed
AT1 decreased cell migration by transwell assays. All values are
xperiments. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4 CCAT1 acts as a molecular sponge for let-7. (A) Bioinformatics predicted let-7 binding sites at two distinct positions in CCAT1. Partial
sequences of CCAT1 and sequences of four let-7 subtypes are shown. Numbers are in nucleotides relative to the transcriptional start site of
CCAT1. (B) Schematic outlining the MS2-RIP strategy to validate endogenous miRNA:CCAT1 binding. (C) MS2-RIP followed by miRNA qRT-PCR to
detect miRNAs endogenously associated with CCAT1. (D) Expression levels of let-7 after the transfection of pcDNA3.1-CCAT1 or pcDNA3.1 into
SMMC-7721 cells. (E) Luciferase activity in SMMC-7721 cells cotransfected with let-7 and luciferase reporters containing nothing, CCAT1 or mutant
CCAT1. Data are presented as the relative ratio of firefly luciferase activity to renilla luciferase activity. (F) CCAT1 expression levels after the transfection
of let-7 mimics or the miRNA negative control into SMMC-7721 cells. All values are presented as mean ± standard error based on at least three
independent experiments. *p < 0.05, **p < 0.01.
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says indicated that the mutation of let-7 binding sites at-
tenuated the promoting migration effect of CCAT1 in
SMMC-7721 cells (Figure 6B). Repression of let-7 over-
came the inhibitory effects of decreasing CCAT1 on cell
proliferation (Figure 6C). Repression of let-7 overcame
the inhibitory effects of decreasing CCAT1 on cell mi-
gration (Figure 6D). These results showed that CCAT1
promotes HCC progression via competitively binding
let-7.Discussion
In this study we examined the expression of long non-
coding RNA CCAT1 in HCC tissues and pair-matched
noncancerous hepatic tissues. Consistent with upregula-
tion of CCAT1 in colon carcinoma and gastric carcinoma
tissues from previous reports, our results demonstrate that
CCAT1 is also upregulated in HCC tissues in comparison
with pair-matched noncancerous hepatic tissues [18,19].
CCAT1 upregulation is correlated with tumor size, micro-
vascular invasion, and AFP. High CCAT1 expression in
Figure 5 Regulation of endogenous let-7 targets by CCAT1. (A) The expression of CCAT1 in stable SMMC-7721 cell clones. (B) HMGA2 and
c-Myc mRNA levels in stable SMMC-7721 cell clones. (C) HMGA2 and c-Myc protein levels in stable SMMC-7721 cell clones. (D, E) The expression of
CCAT1(D) or let-7b (E) in indicated HepG2 cell clones after transfection of let-7 inhibitor. (F) HMGA2 and c-Myc mRNA levels in stable HepG2 cell
clones. (G) HMGA2 and c-Myc mRNA levels in stable HepG2 cell clones. For A-G, all values are presented as mean ± standard error based on at least
three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. (H) The correlation between CCAT1 transcript level and c-Myc mRNA level was
measured in 66 HCC tissues. The delta-Ct values (normalized to 18S rRNA) were subjected to Pearson correlation analysis. (I) Immunohistochemical
scores of CCAT1 in HCC tissues of different CCAT1 expression (Mann–Whitney test, p < 0.001).
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also identified the function of CCAT1 in HCC cells by ap-
plying gain-of-function and loss-of-function approaches.
Enhanced expression of CCAT1 promotes the prolifera-
tion and migration of HCC cells, while inhibition of
CCAT1 inhibits the proliferation and migration of HCC
cells. Therefore, our results indicated that CCAT1 func-
tions as an oncogene in HCC.
Several RNA transcripts, including mRNAs and lncRNAs
have been identified as competing endogenous RNAs
(ceRNAs), such as PTENP1, Linc-MD1, HMGA2, andlncRNA-ATB [14,31-33]. They function as sponges for
common miRNAs and abolished the endogenous suppres-
sive effect of these miRNAs on their bona fide targeted
transcripts. In this study we demonstrated that CCAT1
functions as a molecular sponge for let-7, upregulates ex-
pression of its endogenous targets HMGA2 and c-Myc,
and inhibits its function. Our results also found that
CCAT1 transcript level was significantly correlated with
c-Myc mRNA level and HMGA2 protein level in HCC tis-
sues. Other reports have shown that c-Myc directly bound
the promoter region of CCAT1, and promoted CCAT1
Figure 6 CCAT1 promotes HCC progression by competitively binding let-7. (A) The mutation of let-7 binding sites attenuated the promoting
proliferation effect of CCAT1 in SMMC-7721 cells. Cell number was determined by the CCK-8 assay, and the relative number of cells to 0 h is presented.
(B) The mutation of let-7 binding sites attenuated the promoting migration effect of CCAT1 in SMMC-7721 cells by transwell assays. (C) Repression of
let-7 overcame the inhibitory effects of decreasing CCAT1 on cell proliferation by the CCK-8 assay. (D) Repression of let-7 overcame the inhibitory
effects of decreasing CCAT1 on cell migration by transwell assays. All values are presented as mean ± standard error based on at least three independent
experiments. **p < 0.01, ***p < 0.001.
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[18,34]. The effect of c-Myc on CCAT1 in HCC should be
further investigated. These showed that c-Myc and CCAT1
maybe upregulated each other, and formed a double posi-
tive feedback loop to enhance the robustness of gene net-
works. Let-7 family miRNAs have been reported to be
downregulated in human HCC tissues in comparison
with normal hepatic tissues [35]. It is well recognized that
let-7 play pivotal roles in tumor by inhibiting prolifera-
tion and migration, and inducing apoptosis [26,27]. Our
results demonstrated that through competitively binding
let-7, CCAT1 further inhibits the function of let-7, which
is promoting proliferation and migration of HCC cells.
The effects of CCAT1 on proliferation and migration are
abolished by the mutation of let-7 binding sites. The in-
hibitory effects of depletion of CCAT1 on proliferation
and migration are overcome by inhibition of let-7. These
data support that the role of CCAT1 is dependent upon
its binding to let-7. Recently, H19 and HMGA2 have
been reported to function as ceRNAs for let-7 miRNA
family in different tissues [30,32]. The interactions be-
tween these ceRNAs using let-7 microRNA response ele-
ments in different cell types require further investigation.Conclusions
Collectively, our studies indicate that CCAT1, which is a
prognostic factor for HCC, promotes HCC progression
by functioning as let-7 sponge. These findings indicate
that CCAT1 is an important molecular marker for pre-
dicting prognosis, and an important target for HCC
therapy.
Additional file
Additional file 1: Table S1. The predicted miRNA target sites in CCAT1.
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